ALKERMES | ALKS - Debt

Stock Price
37.48
Daily Change
-0.88 -2.29%
Monthly
11.00%
Yearly
19.29%
Q2 Forecast
36.35

ALKERMES reported $1.58B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Amgen USD 54.6B 17M Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Gilead Sciences USD 24.94B 5M Dec/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
J&J USD 47.93B 2.14B Dec/2025
Malin Corporation EUR 100K 0 Dec/2023
Merck USD 49.34B 7.97B Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Otsuka Holdings JPY 227.98B 16.47B Dec/2025
Ovoca Bio EUR 0 0 Jun/2021
Pfizer USD 63.73B 231M Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026